With its new expansion of the pharmacogenomics research network (PGRN), the National Institutes of Health (NIH) awarded St Jude Children's Research Hospital a prestigious grant to focus on anticancer agent research in children. The five-year, $ 8.6 million grant is titled PAAR4Kids-Pharmacogenomics of Anticancer Agents Research in Children.
"We have been part of the PGRN for 10 years but now, we will be the only PGRN group to focus on children, and we are partnering with NCI's children's oncology group. We will be able to comprehensively study children with acute lymphoblastic leukemia, and we are moving some pharmacogenetic testing into real patient care," informed Mary V Relling, Pharm D, Pharmaceutical Sciences chair at St Jude.
A scientist at St. Jude since 1988, Relling's research focuses on pharmacokinetics and pharmacodynamics in children and how genome variability influences response to cancer chemotherapy. In support of personalised medicine, the NIH has expanded the PGRN, a nationwide group of scientists focused on understanding how genes affect a person's response to medicines. The NIH estimates it will spend $161.3 million over the next five years to expand the network.
Spearheaded by the NIH's national institute of general medical sciences (NIGMS) and launched in 2000, the PGRN has already identified gene variants linked to people's responses to medicines for cancer, heart disease, asthma, nicotine addiction and other conditions. The PGRN projects beginning this summer will build on this decade-old foundation and move the PGRN into several new areas like rheumatoid arthritis, bipolar disorder, and rural and under-served populations.
PAAR4Kids is funded by three NIH components: NIGMS, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Cancer Institute. Other NIH components funding the PGRN include the National Heart, Lung, and Blood Institute; the National Institute on Drug Abuse; the National Human Genome Research Institute; the National Institute of Mental Health; the National Institute of Arthritis and Musculoskeletal and Skin Diseases; and the Office of Research on Women's Health in the Office of the Director.
The project described was supported by Award Number U01GM092666 from the National Institute of General Medical Sciences. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health.
Along with St Jude, the other PGRN research groups include University of California, San Francisco; University of Florida, Gainesville; University of California, San Diego; Children's Hospital Oakland Research Institute, California; University of Pennsylvania, Philadelphia; University of Toronto; Brigham and Women's Hospital, Boston, Massachusetts; The University of Chicago, Ill.; Vanderbilt University School of Medicine, Nashville, Tennessee; The Ohio State University, Columbus; University of Maryland, Baltimore; University of Washington, Seattle; and Mayo Clinic, Rochester, Minnesota.